Simon Quick Advisors LLC Has $3.86 Million Holdings in Johnson & Johnson (NYSE:JNJ)

Simon Quick Advisors LLC increased its stake in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 34.0% during the first quarter, according to the company in its most recent filing with the SEC. The fund owned 23,298 shares of the company's stock after acquiring an additional 5,914 shares during the period. Simon Quick Advisors LLC's holdings in Johnson & Johnson were worth $3,864,000 as of its most recent filing with the SEC.

A number of other institutional investors have also made changes to their positions in JNJ. Capital Advisors Ltd. LLC lifted its stake in shares of Johnson & Johnson by 39.0% in the first quarter. Capital Advisors Ltd. LLC now owns 4,381 shares of the company's stock worth $727,000 after buying an additional 1,229 shares during the last quarter. Zhang Financial LLC lifted its stake in shares of Johnson & Johnson by 42.1% in the first quarter. Zhang Financial LLC now owns 17,590 shares of the company's stock worth $2,917,000 after buying an additional 5,210 shares during the last quarter. Coerente Capital Management lifted its stake in shares of Johnson & Johnson by 0.5% in the first quarter. Coerente Capital Management now owns 159,154 shares of the company's stock worth $26,394,000 after buying an additional 789 shares during the last quarter. Baker Ellis Asset Management LLC increased its position in Johnson & Johnson by 18.5% during the first quarter. Baker Ellis Asset Management LLC now owns 8,779 shares of the company's stock worth $1,456,000 after acquiring an additional 1,368 shares during the period. Finally, Chris Bulman Inc increased its position in Johnson & Johnson by 5.6% during the first quarter. Chris Bulman Inc now owns 2,348 shares of the company's stock worth $389,000 after acquiring an additional 124 shares during the period. 69.55% of the stock is owned by institutional investors.

Johnson & Johnson Price Performance

Shares of NYSE:JNJ traded up $0.24 on Friday, hitting $156.90. The stock had a trading volume of 6,587,488 shares, compared to its average volume of 7,963,253. The firm's 50 day moving average price is $153.84 and its 200-day moving average price is $153.71. The company has a market capitalization of $377.52 billion, a price-to-earnings ratio of 23.59, a price-to-earnings-growth ratio of 2.56 and a beta of 0.42. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. Johnson & Johnson has a twelve month low of $140.68 and a twelve month high of $169.99.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, April 15th. The company reported $2.77 EPS for the quarter, topping analysts' consensus estimates of $2.59 by $0.18. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The firm had revenue of $21.89 billion for the quarter, compared to analyst estimates of $21.65 billion. On average, equities research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Increases Dividend

The business also recently disclosed a quarterly dividend, which was paid on Tuesday, June 10th. Shareholders of record on Tuesday, May 27th were issued a dividend of $1.30 per share. The ex-dividend date was Tuesday, May 27th. This represents a $5.20 dividend on an annualized basis and a yield of 3.31%. This is a positive change from Johnson & Johnson's previous quarterly dividend of $1.24. Johnson & Johnson's dividend payout ratio is currently 57.84%.

Analyst Ratings Changes

A number of equities analysts recently issued reports on JNJ shares. Benchmark raised shares of Johnson & Johnson to a "strong-buy" rating in a research report on Thursday, April 24th. Sanford C. Bernstein reissued a "market perform" rating on shares of Johnson & Johnson in a report on Wednesday, April 16th. The Goldman Sachs Group raised shares of Johnson & Johnson from a "neutral" rating to a "buy" rating and boosted their price target for the company from $157.00 to $172.00 in a report on Wednesday, April 9th. Raymond James lowered their price target on shares of Johnson & Johnson from $165.00 to $162.00 and set an "outperform" rating on the stock in a report on Monday, April 14th. Finally, Wall Street Zen lowered shares of Johnson & Johnson from a "strong-buy" rating to a "buy" rating in a report on Thursday, May 22nd. Eleven analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average target price of $170.88.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.